Gilead Sciences
Tracked across 14 events · 1859 articles · First seen Feb 10, 2025 · Last active Jun 11, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Tech
Impact: Gilead Sciences developed and received approval for lenacapavir (Yeztugo), the twice-a-year HIV prevention shot, which is a significant product for the company.
Jun 18, 2025 · 7 articles
Business
Impact: Gilead Sciences is acquiring Tubulis for up to $5.0 billion, gaining its next-generation antibody-drug conjugate platform and pipeline, which will enhance Gilead's oncology capabilities.
Apr 07, 2026 · 6 articles
Regulatory
The United States — Food and Drug Administration>>> has granted accelerated approval to Gilead Sciences>>>' Hepcludex (bulevirtide-gmod) for the treatment of chronic hepatitis delta virus (HDV) infection in adults in the United States>>>. This marks…
Impact: The approval of Hepcludex by the United States — Food and Drug Administration>>> expands Gilead Sciences>>>' liver disease portfolio and positions it as a primary player in the hepatitis D treatment market. This approval is a significant commercial advancement for Gilead Sciences>>>.
May 22, 2026 · 10 articles
Regulatory
Impact: Gilead Sciences is among the pharmaceutical companies that agreed to lower drug prices for United States — Medicaid and cash payers as part of the deals with the Donald Trump administration.
Dec 19, 2025 · 7 articles
Business
Impact: Gilead Sciences is a pharmaceutical company that has been actively involved in acquisitions this year and is also facing patent expirations on some of its blockbuster drugs.
May 01, 2026 · 6 articles
Tech
South Africa has launched the rollout of Lenacapavir, a highly effective, twice-yearly injectable drug for HIV prevention, marking a significant turning point in the country's fight against HIV. Developed by Gilead Sciences, Lenacapavir demonstrated 100%…
Impact: Gilead Sciences developed Lenacapavir and has committed to granting a voluntary manufacturing license to a South African company, which will allow for cheaper generic versions of the drug.
Jun 09, 2026 · 8 articles
Tech
The World Health Organization has recommended prioritizing three experimental treatments for the Bundibugyo strain of Ebola: Mapp Biopharmaceutical's MBP134, Regeneron Pharmaceuticals' maftivimab, and Gilead Sciences' remdesivir. These, along with other vaccine candidates, are to be…
Impact: Gilead Sciences developed the antiviral remdesivir and experimental oral antiviral obeldesivir, both prioritized by the World Health Organization for treatment and prevention of the Bundibugyo strain of Ebola.
May 28, 2026 · 6 articles
Accidents
A new Ebola outbreak, caused by the Bundibugyo strain, has emerged in the Democratic Republic of the Congo, primarily in Democratic Republic of the Congo — Ituri Province. The outbreak has resulted in over 220…
Impact: Gilead Sciences is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.
May 15, 2026 · 446 articles
Accidents
Impact: Gilead Sciences' antiviral drug remdesivir and experimental drug obeldesivir are being prioritized for clinical trials to treat or prevent the Bundibugyo ebolavirus, indicating its significant role in potential therapies.
May 18, 2026 · 505 articles
International
A severe Ebola outbreak, caused by the rare Bundibugyo strain, is rapidly spreading in the Democratic Republic of the Congo, primarily in Democratic Republic of the Congo — Ituri Province, with cases also confirmed in…
Impact: Gilead Sciences' experimental oral COVID antiviral drug, Obeldesivir, is being considered for use as a preventative treatment for Ebola contacts, under strict protocol.
May 21, 2026 · 627 articles
International
The United States>>> proposed establishing an Ebola quarantine facility in Kenya>>> for its citizens exposed to the virus, aiming to prevent Ebola cases from entering American territory. This plan, a departure from previous administrations' policies…
Impact: Gilead Sciences' antiviral remdesivir is mentioned as a potential treatment to be used at the quarantine facility, indicating its role in the medical response to Ebola.
May 26, 2026 · 206 articles
100
United States — Food and Drug Administration granted accelerated approval Gilead SciencesFDA approves Gilead's Hepcludex
90
Gilead Sciences agreed to provideSouth Africa rolls out lenacapavir
70
Gilead Sciences considering antiviral drug
70
Gilead Sciences committed to granting South AfricaSouth Africa rolls out lenacapavir
+ 52 more relationships
View on Dashboard
NEWSDESK
Track Gilead Sciences live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard